Namiko Nishida - Academia.edu (original) (raw)
Papers by Namiko Nishida
Frontiers in aging neuroscience, Apr 4, 2024
Functional neurosurgery : proceedings of the annual meeting of the Japan Society for Stereotactic and Functional Neurosurgery, Jun 10, 2008
Neuro-oncology, Nov 1, 2015
Internal Medicine, Jun 1, 2021
A 76-year-old man taking prednisolone for organized pneumonia presented with fatigue and consciou... more A 76-year-old man taking prednisolone for organized pneumonia presented with fatigue and consciousness disturbance progressing over a week. He had no fever or headache. He could follow only simple commands and showed weakness of the right upper extremity and bilateral Babinski signs. His neck was supple. T2-weighted and fluidattenuated inversion recovery imaging showed ventricular enlargement with periventricular edema, and gadoliniumenhanced imaging showed thin linear enhancement along the ventricular walls, characteristic findings of infectious ventriculitis (1). There was no diffusion restriction (Picture 1). Chest-abdominal computed tomography findings were unremarkable. Blood tests showed hyponatremia but a normal Creactive protein level. Treponemal antibodies were negative.
Brain Tumor Pathology, Jun 1, 2005
We report here an intractable epilepsy case with fairly typical clinicoradiological features of d... more We report here an intractable epilepsy case with fairly typical clinicoradiological features of dysembryoplastic neuroepithelial tumor (DNT), which means onset of seizures at a young age accompanying a medial temporal cystic lesion enclosed in cortical dysplasia (CD). The medial cystic lesion was composed of two morphologically distinct components; one was oligo-like and the other showed some tendency toward neuronal and glial differentiation, even though they were morphologically different from a so-called specific glioneural element (SGE). Epileptiform discharges were detected not only on the medial lesion but also on the lateral inferior temporal gyrus, which was confirmed as CD. According to both histopathological and clinical features, we named the lesion a nonspecific form of DNT.
Neurosurgical Focus, Apr 1, 2017
Holmes tremor is often treated with multiple deep brain stimulation (DBS) electrodes. The authors... more Holmes tremor is often treated with multiple deep brain stimulation (DBS) electrodes. The authors describe a novel technique to suppress the tremors by effectively utilizing a single electrode. A 16-year-old boy presented with severe right arm tremor following a midbrain injury. A DBS electrode was implanted into the ventral oralis nucleus of the thalamus (VO) and the subthalamic region. While individual stimulation of each target was ineffective, an interleaved dual stimulation of both targets has been effective for 6 years. Coaxial interleaved stimulation of the VO and the subthalamic region is useful for treating Holmes tremor. The video can be found here: https://youtu.be/tSwGh3vy68c.
Figure S8. Expression data of (a) EP300, (b) BCORL1, (c) FOXO1, and (d) STK24 among supratentoria... more Figure S8. Expression data of (a) EP300, (b) BCORL1, (c) FOXO1, and (d) STK24 among supratentorial ependymomas. EP3 and EP57 show by far the highest expression levels of BCORL1 and FOXO1 among all ST-EPNs, respectively. (TIF 5041 kb)
Neuro-Oncology, 2017
Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers p... more Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers patients with glioblastoma who survived for at least 5 years. The aim of the study is a better understanding of factors contributing to prolonged survival by assessment of (i) clinical features, (ii) molecular parameters, (iii) therapy and quality of life-related factors, and (iv) immunological parameters. The histopathological diagnosis of glioblastoma is centrally reviewed at study entry. Clinical characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Comprehensive molecular analyses are performed at the German Cancer Research Center (DKFZ), Germany. Immunological parameters are analyzed in Zurich, Switzerland. Alive patients are followed by neurocognitive assessments additionally. RESULTS: At the cutoff of May 30, 2017, 182 patients have been registered by 17 sites; 107 patients are alive, more than half of which contribute to the neurocognitive assessments and patient-related outcome studies, as well as the immunological studies. First comprehensive results of disease characteristics with a cutoff of September 30, 2017, will be presented. CONCLUSIONS: The collaborative effort of this consortium by comprehensive characterization of molecular parameters, immunological aspects, and individual clinical and therapy-related determinants will contribute to a better understanding of factors that modulate the course of this disease.
Pilocytic astrocytoma is a benign World Health Organization (WHO) grade 1 tumor and usually occur... more Pilocytic astrocytoma is a benign World Health Organization (WHO) grade 1 tumor and usually occurs in young patients. This tumor can occur in adults, yet relatively few arise in those who are older than 50 years. The tumor histology is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and loose-textured multipolar cells associated with microcysts and eosinophilic granular bodies/hyaline droplets. Tumor growth is always slow, and occasionally regressive changes are observed. Such spontaneous regression has been described mainly for tumors in children and associated with neurofibromatosis type 1 (NF1) , yet also reported for non NF1 young adult patients. We report here a unique case of pilocytic astrocytoma diagnosed for 64-year-old woman. This case is noteworthy in following points: the patient was an elderly adult without clear comorbidity; the patient's tumor spontaneously regressed in short term before surgery.
No shinkei geka. Neurological surgery, 2021
This article reviews the stereotactic targets in the posterior subthalamic area(PSA), fields H1/H... more This article reviews the stereotactic targets in the posterior subthalamic area(PSA), fields H1/H2 of Forel(pallidothalamic tract), and the pedunculopontine nucleus(PPN)to complement the preceding articles on stereotactic and functional neurosurgery for movement disorders in the present issue of No Shinkei Geka. Two regions within the subthalamus, the PSA and fields H1/H2 of Forel, are the revisited stereotactic targets to treat movement disorders. Currently, the PSA is often utilized to treat essential tremor and various types of tremor. Fields H1/H2 of Forel are investigated as a target for magnetic resonance-guided focused ultrasound to treat motor symptoms and motor complications in patients with Parkinson's disease. For the past twenty years, the PPN has been investigated to treat refractory gait freezing and fall in patients with Parkinson's disease. These revisited and novel targets may be utilized as substitutes and complements for the present standard stereotactic t...
Neuro-Oncology, 2019
The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozo... more The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemoregimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2/day) (Day 1–5) plus various doses of ACNU (30, 35, 40, 45 mg/m2/day) (Day 15) per 4 weeks was defined on a standard 3 + 3 design. In phase II, these therapeutic activity and safety of this regimen were evaluated. Forty-nine eligible patients were enrolled. The median age was 50 years-old. Eighty percent had a KPS of 70–100. Histologies were glioblastoma (73%), anaplastic astrocytoma (22%), anaplastic oligodendroglioma (4%). In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150 mg/m2) plus ACNU (40 mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients experienced grade 3 or 4 toxicities, mainly hematol...
Scientific Reports, 2019
We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for stratifying... more We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and predicting O (6)-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) status of the tumor. Preoperative MRI scans from 201 newly diagnosed GBM patients were included in this study. A total of 489 texture features including the first-order feature, second-order features from 162 datasets, and location data from 182 datasets were collected. Supervised principal component analysis was used for prognostication and predictive modeling for pMGMT-met status was performed based on least absolute shrinkage and selection operator regression. 22 radiomic features that were correlated with prognosis were used to successfully stratify patients into high-risk and low-risk groups (p = 0.004, Log-rank test). The radiomic high- and low-risk stratification and pMGMT status were independent prognostic factors. As a mat...
Clinical Neurophysiology, Oct 1, 2010
independently chosen for chronic DBS (Spearman’s rho = 0.35, p = 0.01). In addition, the absolute... more independently chosen for chronic DBS (Spearman’s rho = 0.35, p = 0.01). In addition, the absolute difference between the depths of the initial increase in beta and the contact chosen for chronic DBS correlated with the voltage used for chronic stimulation (rho = 0.322, p = 0.017). Thus more voltage had to be employed if a depth was selected for chronic stimulation that differed from that of the beta generator. Conclusions: On-line spectral analysis of LFPs recorded from the DBS electrode may help identify the optimal therapeutic target in the STN region for DBS.
Figure S2. Classification of posterior fossa (PF-EPN) and spinal ependymomas (SP-EPN) using genom... more Figure S2. Classification of posterior fossa (PF-EPN) and spinal ependymomas (SP-EPN) using genome-wide methylation profiling. A heatmap analyzed by 3932 probes that showed high standard deviations (SDâ >â 0.25) on CpG islands for unsupervised hierarchical clustering of 72 centrally-diagnosed posterior and spinal ependymoma samples shows that nearly all spinal tumors except one (EP114) were clustered with posterior fossa PFB. The following information is indicated below the heatmap: tumor location, a pattern of PF tumors extension, pathological grading, the presence of 1q gain, age at onset, and the DKFZ classifier result. (TIF 6031 kb)
Figure S1. (a) Electropherograms of novel fusion transcripts detected in ST-EPNs. (b) Copy number... more Figure S1. (a) Electropherograms of novel fusion transcripts detected in ST-EPNs. (b) Copy number analysis of EP57 showing copy number oscillation in chromosome 6 and 13 (The DKFZ Classifier output, molecularneuropathology.org ). (TIF 7893 kb)
Table S2. Candidate probes in screening set for pyrosequencing assay (XLSX 11 kb)
PLOS ONE, 2020
Cluster of differentiation (CD) 166 or activated leukocyte cell adhesion molecule (ALCAM) is a tr... more Cluster of differentiation (CD) 166 or activated leukocyte cell adhesion molecule (ALCAM) is a transmembrane molecule known to be an intercellular adhesion factor. The expression and function of ALCAM in medulloblastoma (MB), a pediatric brain tumor with highly advanced molecular genetics, remains unclear. Therefore, this study aimed to clarify the significance and functional role of ALCAM expression in MB. ALCAM expression in 45 patients with MB was evaluated by immunohistochemical analysis of formalin-fixed paraffin-embedded clinical specimens and the relationship between ALCAM expression and pathological type/molecular subgroup, such as WNT, SHH, Group 3, and Group 4, was examined. Eight ALCAM positive (18%), seven partially positive (16%), and 30 negative (67%) cases were detected. All seven cases of the WNT molecular subgroup were ALCAM positive and ALCAM expression strongly correlated with this subgroup (P < 0.0001). In addition, functional studies using MB cell lines revea...
Neuro-Oncology, Nov 1, 2017
Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblasto... more Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same period, BCNU wafer was also able to be administered. The objective of this study was to examine the influence upon treatment of Glioblastoma that these new therapeutic modalities had, and to find the most popular treatment for glioblastomas in Kansai region, Japan. For this purpose, we retrospectively reviewed clinical data of 223 newly diagnosed glioblastoma patients which were collected for molecular biological analysis by Kansai Molecular Diagnosis Network for CNS Tumors between 2006 and 2016. We examined how treatments of glioblastoma altered after 2013. In 79 patients diagnosed before June 2013, 68 (86.1%) were received concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ), three (3.8%) radiation therapy (RT) only, four (5.1%) chemotherapy (CMT) only, and four (5.1%) none. In 144 patients after that, 113 (78.5%) were received CCRT, six (4.2%) RT only, 19 (13.8%) CMT only, and six (4.2%)none. Bevacizumab was used for 29 patients (20.1%) at initial treatment, 21 (14.6%) at recurrence, and 13 (9.0%) throughout. That is, only about half of glioblastoma patients were treated with Bev. We also found that TMZ were still most frequently used for treatment after recurrence, and nitrosourea was not used at all since 2013. Significant alterations observed were increase of TMZ chemotherapy without RT and use of reduced radiation dose, which were mainly selected based on methylation status of MGMT promoter and patients’ age. Finally, it seems that more personalized treatment for glioblastoma has been introducing in these days, but additional treatment resulting to improvement of prognosis has not become popular.
Frontiers in aging neuroscience, Apr 4, 2024
Functional neurosurgery : proceedings of the annual meeting of the Japan Society for Stereotactic and Functional Neurosurgery, Jun 10, 2008
Neuro-oncology, Nov 1, 2015
Internal Medicine, Jun 1, 2021
A 76-year-old man taking prednisolone for organized pneumonia presented with fatigue and consciou... more A 76-year-old man taking prednisolone for organized pneumonia presented with fatigue and consciousness disturbance progressing over a week. He had no fever or headache. He could follow only simple commands and showed weakness of the right upper extremity and bilateral Babinski signs. His neck was supple. T2-weighted and fluidattenuated inversion recovery imaging showed ventricular enlargement with periventricular edema, and gadoliniumenhanced imaging showed thin linear enhancement along the ventricular walls, characteristic findings of infectious ventriculitis (1). There was no diffusion restriction (Picture 1). Chest-abdominal computed tomography findings were unremarkable. Blood tests showed hyponatremia but a normal Creactive protein level. Treponemal antibodies were negative.
Brain Tumor Pathology, Jun 1, 2005
We report here an intractable epilepsy case with fairly typical clinicoradiological features of d... more We report here an intractable epilepsy case with fairly typical clinicoradiological features of dysembryoplastic neuroepithelial tumor (DNT), which means onset of seizures at a young age accompanying a medial temporal cystic lesion enclosed in cortical dysplasia (CD). The medial cystic lesion was composed of two morphologically distinct components; one was oligo-like and the other showed some tendency toward neuronal and glial differentiation, even though they were morphologically different from a so-called specific glioneural element (SGE). Epileptiform discharges were detected not only on the medial lesion but also on the lateral inferior temporal gyrus, which was confirmed as CD. According to both histopathological and clinical features, we named the lesion a nonspecific form of DNT.
Neurosurgical Focus, Apr 1, 2017
Holmes tremor is often treated with multiple deep brain stimulation (DBS) electrodes. The authors... more Holmes tremor is often treated with multiple deep brain stimulation (DBS) electrodes. The authors describe a novel technique to suppress the tremors by effectively utilizing a single electrode. A 16-year-old boy presented with severe right arm tremor following a midbrain injury. A DBS electrode was implanted into the ventral oralis nucleus of the thalamus (VO) and the subthalamic region. While individual stimulation of each target was ineffective, an interleaved dual stimulation of both targets has been effective for 6 years. Coaxial interleaved stimulation of the VO and the subthalamic region is useful for treating Holmes tremor. The video can be found here: https://youtu.be/tSwGh3vy68c.
Figure S8. Expression data of (a) EP300, (b) BCORL1, (c) FOXO1, and (d) STK24 among supratentoria... more Figure S8. Expression data of (a) EP300, (b) BCORL1, (c) FOXO1, and (d) STK24 among supratentorial ependymomas. EP3 and EP57 show by far the highest expression levels of BCORL1 and FOXO1 among all ST-EPNs, respectively. (TIF 5041 kb)
Neuro-Oncology, 2017
Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers p... more Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers patients with glioblastoma who survived for at least 5 years. The aim of the study is a better understanding of factors contributing to prolonged survival by assessment of (i) clinical features, (ii) molecular parameters, (iii) therapy and quality of life-related factors, and (iv) immunological parameters. The histopathological diagnosis of glioblastoma is centrally reviewed at study entry. Clinical characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Comprehensive molecular analyses are performed at the German Cancer Research Center (DKFZ), Germany. Immunological parameters are analyzed in Zurich, Switzerland. Alive patients are followed by neurocognitive assessments additionally. RESULTS: At the cutoff of May 30, 2017, 182 patients have been registered by 17 sites; 107 patients are alive, more than half of which contribute to the neurocognitive assessments and patient-related outcome studies, as well as the immunological studies. First comprehensive results of disease characteristics with a cutoff of September 30, 2017, will be presented. CONCLUSIONS: The collaborative effort of this consortium by comprehensive characterization of molecular parameters, immunological aspects, and individual clinical and therapy-related determinants will contribute to a better understanding of factors that modulate the course of this disease.
Pilocytic astrocytoma is a benign World Health Organization (WHO) grade 1 tumor and usually occur... more Pilocytic astrocytoma is a benign World Health Organization (WHO) grade 1 tumor and usually occurs in young patients. This tumor can occur in adults, yet relatively few arise in those who are older than 50 years. The tumor histology is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and loose-textured multipolar cells associated with microcysts and eosinophilic granular bodies/hyaline droplets. Tumor growth is always slow, and occasionally regressive changes are observed. Such spontaneous regression has been described mainly for tumors in children and associated with neurofibromatosis type 1 (NF1) , yet also reported for non NF1 young adult patients. We report here a unique case of pilocytic astrocytoma diagnosed for 64-year-old woman. This case is noteworthy in following points: the patient was an elderly adult without clear comorbidity; the patient's tumor spontaneously regressed in short term before surgery.
No shinkei geka. Neurological surgery, 2021
This article reviews the stereotactic targets in the posterior subthalamic area(PSA), fields H1/H... more This article reviews the stereotactic targets in the posterior subthalamic area(PSA), fields H1/H2 of Forel(pallidothalamic tract), and the pedunculopontine nucleus(PPN)to complement the preceding articles on stereotactic and functional neurosurgery for movement disorders in the present issue of No Shinkei Geka. Two regions within the subthalamus, the PSA and fields H1/H2 of Forel, are the revisited stereotactic targets to treat movement disorders. Currently, the PSA is often utilized to treat essential tremor and various types of tremor. Fields H1/H2 of Forel are investigated as a target for magnetic resonance-guided focused ultrasound to treat motor symptoms and motor complications in patients with Parkinson's disease. For the past twenty years, the PPN has been investigated to treat refractory gait freezing and fall in patients with Parkinson's disease. These revisited and novel targets may be utilized as substitutes and complements for the present standard stereotactic t...
Neuro-Oncology, 2019
The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozo... more The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemoregimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2/day) (Day 1–5) plus various doses of ACNU (30, 35, 40, 45 mg/m2/day) (Day 15) per 4 weeks was defined on a standard 3 + 3 design. In phase II, these therapeutic activity and safety of this regimen were evaluated. Forty-nine eligible patients were enrolled. The median age was 50 years-old. Eighty percent had a KPS of 70–100. Histologies were glioblastoma (73%), anaplastic astrocytoma (22%), anaplastic oligodendroglioma (4%). In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150 mg/m2) plus ACNU (40 mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients experienced grade 3 or 4 toxicities, mainly hematol...
Scientific Reports, 2019
We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for stratifying... more We attempted to establish a magnetic resonance imaging (MRI)-based radiomic model for stratifying prognostic subgroups of newly diagnosed glioblastoma (GBM) patients and predicting O (6)-methylguanine-DNA methyltransferase promotor methylation (pMGMT-met) status of the tumor. Preoperative MRI scans from 201 newly diagnosed GBM patients were included in this study. A total of 489 texture features including the first-order feature, second-order features from 162 datasets, and location data from 182 datasets were collected. Supervised principal component analysis was used for prognostication and predictive modeling for pMGMT-met status was performed based on least absolute shrinkage and selection operator regression. 22 radiomic features that were correlated with prognosis were used to successfully stratify patients into high-risk and low-risk groups (p = 0.004, Log-rank test). The radiomic high- and low-risk stratification and pMGMT status were independent prognostic factors. As a mat...
Clinical Neurophysiology, Oct 1, 2010
independently chosen for chronic DBS (Spearman’s rho = 0.35, p = 0.01). In addition, the absolute... more independently chosen for chronic DBS (Spearman’s rho = 0.35, p = 0.01). In addition, the absolute difference between the depths of the initial increase in beta and the contact chosen for chronic DBS correlated with the voltage used for chronic stimulation (rho = 0.322, p = 0.017). Thus more voltage had to be employed if a depth was selected for chronic stimulation that differed from that of the beta generator. Conclusions: On-line spectral analysis of LFPs recorded from the DBS electrode may help identify the optimal therapeutic target in the STN region for DBS.
Figure S2. Classification of posterior fossa (PF-EPN) and spinal ependymomas (SP-EPN) using genom... more Figure S2. Classification of posterior fossa (PF-EPN) and spinal ependymomas (SP-EPN) using genome-wide methylation profiling. A heatmap analyzed by 3932 probes that showed high standard deviations (SDâ >â 0.25) on CpG islands for unsupervised hierarchical clustering of 72 centrally-diagnosed posterior and spinal ependymoma samples shows that nearly all spinal tumors except one (EP114) were clustered with posterior fossa PFB. The following information is indicated below the heatmap: tumor location, a pattern of PF tumors extension, pathological grading, the presence of 1q gain, age at onset, and the DKFZ classifier result. (TIF 6031 kb)
Figure S1. (a) Electropherograms of novel fusion transcripts detected in ST-EPNs. (b) Copy number... more Figure S1. (a) Electropherograms of novel fusion transcripts detected in ST-EPNs. (b) Copy number analysis of EP57 showing copy number oscillation in chromosome 6 and 13 (The DKFZ Classifier output, molecularneuropathology.org ). (TIF 7893 kb)
Table S2. Candidate probes in screening set for pyrosequencing assay (XLSX 11 kb)
PLOS ONE, 2020
Cluster of differentiation (CD) 166 or activated leukocyte cell adhesion molecule (ALCAM) is a tr... more Cluster of differentiation (CD) 166 or activated leukocyte cell adhesion molecule (ALCAM) is a transmembrane molecule known to be an intercellular adhesion factor. The expression and function of ALCAM in medulloblastoma (MB), a pediatric brain tumor with highly advanced molecular genetics, remains unclear. Therefore, this study aimed to clarify the significance and functional role of ALCAM expression in MB. ALCAM expression in 45 patients with MB was evaluated by immunohistochemical analysis of formalin-fixed paraffin-embedded clinical specimens and the relationship between ALCAM expression and pathological type/molecular subgroup, such as WNT, SHH, Group 3, and Group 4, was examined. Eight ALCAM positive (18%), seven partially positive (16%), and 30 negative (67%) cases were detected. All seven cases of the WNT molecular subgroup were ALCAM positive and ALCAM expression strongly correlated with this subgroup (P < 0.0001). In addition, functional studies using MB cell lines revea...
Neuro-Oncology, Nov 1, 2017
Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblasto... more Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same period, BCNU wafer was also able to be administered. The objective of this study was to examine the influence upon treatment of Glioblastoma that these new therapeutic modalities had, and to find the most popular treatment for glioblastomas in Kansai region, Japan. For this purpose, we retrospectively reviewed clinical data of 223 newly diagnosed glioblastoma patients which were collected for molecular biological analysis by Kansai Molecular Diagnosis Network for CNS Tumors between 2006 and 2016. We examined how treatments of glioblastoma altered after 2013. In 79 patients diagnosed before June 2013, 68 (86.1%) were received concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ), three (3.8%) radiation therapy (RT) only, four (5.1%) chemotherapy (CMT) only, and four (5.1%) none. In 144 patients after that, 113 (78.5%) were received CCRT, six (4.2%) RT only, 19 (13.8%) CMT only, and six (4.2%)none. Bevacizumab was used for 29 patients (20.1%) at initial treatment, 21 (14.6%) at recurrence, and 13 (9.0%) throughout. That is, only about half of glioblastoma patients were treated with Bev. We also found that TMZ were still most frequently used for treatment after recurrence, and nitrosourea was not used at all since 2013. Significant alterations observed were increase of TMZ chemotherapy without RT and use of reduced radiation dose, which were mainly selected based on methylation status of MGMT promoter and patients’ age. Finally, it seems that more personalized treatment for glioblastoma has been introducing in these days, but additional treatment resulting to improvement of prognosis has not become popular.